Please login to the form below

Not currently logged in


This page shows the latest Dermira news and features for those working in and with pharma, biotech and healthcare.

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

Morgan Healthcare Conference, shortly after the company said it will acquire California-based biotech Dermira for a healthy $1.1bn. ... We are looking at Dermira-like opportunities targeting assets in the $1bn to $5bn range,” Smiley told Reuters.

Latest news

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company. ... This is probably as much as Dermira can afford. It estimates that the development cost will be $200m to get the top line phase IIb study results and has cash

  • Deal Watch September 2016 Deal Watch September 2016

    Royalty range 4 -10%. 150. Dermira / Maruho. Licence. Exclusive licence to DRM04 topical anticholinergic for axillary hyperhidrosis; upfront $25m.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    107. UCB/ Dermira. Licence ††. Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis).

  • Pharma deals during July 2014 Pharma deals during July 2014

    dermatology specialist Dermira to develop Cimzia for psoriasis in the US, Canada and the EU. ... in Dermira and will invest up to a further $15m in its partner's future equity financings.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...